A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme

Many B cell cancers are characterized in part by the dysregulation of the NF-κB signaling pathway. A new study identifies somatic mutations in TNFAIP3, the gene encoding the NF-κB inhibitor A20, in Hodgkin lymphomas and primary mediastinal lymphomas. These data reveal the role of A20 as a tumor supp...

Descripción completa

Detalles Bibliográficos
Autores principales: Malynn, Barbara A., Ma, Averil
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2009
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715039/
https://www.ncbi.nlm.nih.gov/pubmed/19380636
http://dx.doi.org/10.1084/jem.20090765
Descripción
Sumario:Many B cell cancers are characterized in part by the dysregulation of the NF-κB signaling pathway. A new study identifies somatic mutations in TNFAIP3, the gene encoding the NF-κB inhibitor A20, in Hodgkin lymphomas and primary mediastinal lymphomas. These data reveal the role of A20 as a tumor suppressor protein.

Ejemplares similares